Ability of adipoyl phosphonate to specifically regulate the DHTKD1-encoded protein in vivo may be useful to develop combinatorial therapies correcting pathological states associated with changed DHTKD1 expression, among which are insulin resistance, obesity, and cancer. Here, DHTKD1 is linked to obesity due to melanocortin 4 receptor deficiency.